Literature DB >> 27911734

The spatiotemporal regulation of RAS signalling.

Ana Herrero1, David Matallanas1,2, Walter Kolch1,2,3.   

Abstract

Nearly 30% of human tumours harbour mutations in RAS family members. Post-translational modifications and the localisation of RAS within subcellular compartments affect RAS interactions with regulator, effector and scaffolding proteins. New insights into the control of spatiotemporal RAS signalling reveal that activation kinetics and subcellular compartmentalisation are tightly coupled to the generation of specific biological outcomes. Computational modelling can help utilising these insights for the identification of new targets and design of new therapeutic approaches.
© 2016 The Author(s); published by Portland Press Limited on behalf of the Biochemical Society.

Entities:  

Keywords:  RAS; cellular localisation; site-specific signalling

Mesh:

Substances:

Year:  2016        PMID: 27911734     DOI: 10.1042/BST20160127

Source DB:  PubMed          Journal:  Biochem Soc Trans        ISSN: 0300-5127            Impact factor:   5.407


  12 in total

Review 1.  The impact of phosphatases on proliferative and survival signaling in cancer.

Authors:  Goutham Narla; Jaya Sangodkar; Christopher B Ryder
Journal:  Cell Mol Life Sci       Date:  2018-05-03       Impact factor: 9.261

2.  Proximal Protein Interaction Landscape of RAS Paralogs.

Authors:  Benoît Béganton; Etienne Coyaud; Estelle M N Laurent; Alain Mangé; Julien Jacquemetton; Muriel Le Romancer; Brian Raught; Jérôme Solassol
Journal:  Cancers (Basel)       Date:  2020-11-11       Impact factor: 6.639

3.  Magnetic spatiotemporal control of SOS1 coupled nanoparticles for guided neurite growth in dopaminergic single cells.

Authors:  Fabian Raudzus; Hendrik Schöneborn; Sebastian Neumann; Emilie Secret; Aude Michel; Jérome Fresnais; Oliver Brylski; Christine Ménager; Jean-Michel Siaugue; Rolf Heumann
Journal:  Sci Rep       Date:  2020-12-31       Impact factor: 4.379

Review 4.  The Ins and Outs of RAS Effector Complexes.

Authors:  Christina Kiel; David Matallanas; Walter Kolch
Journal:  Biomolecules       Date:  2021-02-07

Review 5.  Hidden Targets in RAF Signalling Pathways to Block Oncogenic RAS Signalling.

Authors:  Aoife A Nolan; Nourhan K Aboud; Walter Kolch; David Matallanas
Journal:  Genes (Basel)       Date:  2021-04-10       Impact factor: 4.096

Review 6.  Toward Understanding the Molecular Role of SNX27/Retromer in Human Health and Disease.

Authors:  Mintu Chandra; Amy K Kendall; Lauren P Jackson
Journal:  Front Cell Dev Biol       Date:  2021-04-15

7.  Functional signaling test identifies HER2 negative breast cancer patients who may benefit from c-Met and pan-HER combination therapy.

Authors:  Ian A MacNeil; Salmaan A Khan; Adrish Sen; Sajjad M Soltani; David J Burns; Brian F Sullivan; Lance G Laing
Journal:  Cell Commun Signal       Date:  2022-01-08       Impact factor: 5.712

8.  Oncogenic KRAS is dependent upon an EFR3A-PI4KA signaling axis for potent tumorigenic activity.

Authors:  Hema Adhikari; Walaa E Kattan; Shivesh Kumar; Pei Zhou; John F Hancock; Christopher M Counter
Journal:  Nat Commun       Date:  2021-09-09       Impact factor: 17.694

Review 9.  A Driver Never Works Alone-Interplay Networks of Mutant p53, MYC, RAS, and Other Universal Oncogenic Drivers in Human Cancer.

Authors:  Maria Grzes; Magdalena Oron; Zuzanna Staszczak; Akanksha Jaiswar; Magdalena Nowak-Niezgoda; Dawid Walerych
Journal:  Cancers (Basel)       Date:  2020-06-11       Impact factor: 6.639

10.  All over the place: deciphering HRAS signaling from different subcellular compartments.

Authors:  Walter Kolch; David Matallanas
Journal:  Mol Cell Oncol       Date:  2019-05-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.